U.S., Jan. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07361029) titled 'CD19 Chimeric Antigen Receptor (CAR) T Cells in Adults With Relapsed/Refractory CD19 Positive Acute Lymphoblastic Leukemia' on Aug. 27, 2025.
Brief Summary: This is a Phase Ia, open label, dose finding single center trial designed to evaluate the maximum tolerated dose, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of CD19 CAR T cells targeting the B cell surface antigen CD19 following administration of chemotherapy lymphodepletion regimen in adults (age 18 - 75) with relapsed/refractory acute lymphoblastic leukemia (ALL).
Study Start Date: July 29, 2025
Study Type: INTERVENTIONAL
Condition:
Relapsed Refr...